Werner Baumann, Bayer CEO (Malte Ossowski/SVEN SIMON/picture-alliance/dpa/AP Images)
March 1, 2022 01:55 PM EST
Bioregnum
Pharma

Bay­er rush­es sup­port to Ukraine staff, help­ing with cash and hous­ing as Rus­sians at­tack ma­jor cities

Bay­er ex­ecs cov­ered all the ma­jor pock­et­book is­sues you’d ex­pect in its Q4 call with an­a­lysts to­day. But clear­ly the in­va­sion of Ukraine — and the …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times